Biomarker-driven individualized treatment in oncology has made tremendous progress through technological developments, new therapeutic modalities and a deeper understanding of the molecular biology for tumors, cancer stem cells and tumor-infiltrating immune cells. Recent technical developments have led to the establishment of a variety of cancer-related diagnostic, prognostic and predictive biomarkers. In this regard, different modern OMICs approaches were assessed in order to categorize and classify prognostically different forms of neoplasia. Despite those technical advancements, the extent of molecular heterogeneity at the individual cell level in human tumors remains largely uncharacterized. Each tumor consists of a mixture of heterogeneous cell types. Therefore, it is important to quantify the dynamic cellular variations in order to predict clinical parameters, such as a response to treatment and or potential for disease recurrence. Recently, single-cell based methods have been developed to characterize the heterogeneity in seemingly homogenous cancer cell populations prior to and during treatment. In this review, we highlight the recent advances for single-cell analysis and discuss the challenges and prospects for molecular characterization of cancer cells, cancer stem cells and tumor-infiltrating immune cells.
INTRODUCTION
In principle, three main classes of biomarkers are distinguished for cancer disease stratification: Diagno stic, prognostic and predictive biomarkers [14] . In onco logy, the diagnostic biomarkers essentially serve to substantiate a specific entity association and suspected malignant diseasespreading pattern. Classical exam ples are the in situ immunophenotyping of a neoplasm such as lung cancer [5] by immunohistology as well as the specific representation of entitydefining molecules such as prostatespecific membrane antigen in prostate cancer [6] . By contrast, prognostic biomarkers have the fun ction of predicting the natural course of a malignant disease. These include classical parameters such as clinical and pathological staging but also the collection of molecular factors, such as tumor specific genetic ab errations (chromosomal abnormalities, gene mutations, pathologic epigenetic changes or dysregulated genes/ pathways) that may be associated with more aggressive disease progression. However, a prognostic biomarker has only a limited value for the patient, since mere knowledge about the prognosis of disease alone has little benefit [2, 4, 7] . The predictive biomarkers specifically describe the expected likelihood of a patient responding to an avai lable therapy option based on the molecular properties of the tumor. This concept is currently used in the context of targeted drugbased tumor treatment with targeted 161 WJSC|www.wjgnet.com Radpour R et al . Molecular biomarkers for tumor cells drugs, e.g., with inhibitors of the epidermal growth factor receptor (EGFR) in the presence of a tissuebased EGFR mutation in lung carcinomas [8] or CD70CD27 signaling in leukemia including acute myeloid leukemia (AML) [9] or chronic myeloid leukemia (CML) [10] . However, there are only a few approved tissuebased predictive biomarkers available. Predictive analytics using molecular imaging and bloodbased technologies are still at the stage of development.
The boundaries between these biomarker types can be blurred. For example, a pathologic genetic altera tion in different situations may represent a diagnostic, a prognostic, and a predictive biomarker. This is illustra ted by the BRAF mutation, as it can support the early diagnosis of a thyroid carcinoma [11] , prognostically define an unfavorable subtype of colorectal carcinoma [4] and predictably provide therapy with a BRAFspecific sm all molecule inhibitor (e.g., vemurafenib) in malignant melanoma [12] . Classical macroscopically assisted histomorpholo gic evaluation of a malignant tumor remains by far the most significant diagnostic, prognostic and in many respects predictive biomarker with the greatest impact on patient treatment. Nevertheless, in recent decades, a refinement of biomarker analysis by molecular meth ods has found its way into pathological diagnostics and shaped the new area of individualized medicine.
CANCER STEM CELLS
Cancer stem cells (CSCs) or tumor precursor cells are a minor fraction of cells within the bulk tumor population, which, because of their unique stem cell properties of relative quiescence and selfrenewal, have been fo und to reconstitute and propagate the tumor and are considered to be essential for tumor neoplasm and me tastasis [13] . The theory of CSCs was firstly postulated in the 1970s and was experimentally confirmed by the isolation of tumorinitiating cells in AML [14] . Furthermore, CSC has been demonstrated in a variety of solid tum ors, such as tumors in brain, colorectal, hematopoie tic malignancies (e.g., myeloid or lymphoid leukemia), head and neck, mammary glands, lung, liver, melanoma and also prostate carcinomas [9, 10, 15, 16] . Heterogeneity is a major hallmark of tumor cells including CSCs. Each cancer cell clone is characterized by harboring different combinations of mutations or genetic alterations, and subsequently the processes of tumorigenesis occur dif ferently based on the type of genetic lesions [17] . CSCs are often resistant against standard therapies such as irradiation, chemotherapy, cytotoxic drugs and probably also against immune attack. This may be due to different escape mechanisms of CSCs and/or due to protective mechanisms of the microenvironment. Un ravelling the function of the CSCs has been one of the main challenges of cancer research [16, 18] . November 26, 2018|Volume 10|Issue 11|
HIGH-THROUGHPUT TECHNOLOGIES FOR PROFILING OF CANCER CELLS AND CSCs
Over the past few decade, a variety of biomarkers for a wide range of solid tumors and hematopoietic malignancies has been identified [2, 4] . The technologies for biomarker analysis are developing rapidly. The next generation sequencing (NGS) technology promptly follows some of the technologies mentioned above, which will lead to further dynamization of the biomarker discovery in oncology. In addition, bloodbased assays using circulating cell free DNA that move beyond the classic tumor marker determination will become more important for the monitoring of disease processes and resistance as well as the prediction of therapy out come [16, 1921] . Mutational analysis in EGFRmutated lung carcinoma prior to therapy with Osimertinib is an exam ple of a bloodbased assay that has already found way into the routine diagnostic pipelines [22] . Further assays are being developed to trace and target circulating tumor cells (mainly CSCs) in the blood, urine, cerebros pinal fluid and other body fluids. The goal must be to transfer molecular markers from tissue diagnostics into noninvasive molecular profiling approaches.
MOLECULAR BIOMARKERS OF CANCER

CELLS AND CSCs
Proteomics
Targeted proteomics using tissuebased in situ methods such as immunohistology has been developed as an important biomarker analysis tool in oncology [23] . This approach is used in many areas of pathology including pathological oncology, and the predictive biomarker an alysis still relies significantly on this method. Examples include the analysis of human epidermal growth factor receptor 2 (HER2) expression prior to treatment with HER2 inhibitors (e.g., trastuzumab) in gastric and breast carcinoma [24, 25] as well as the stratifying assignment of treatment with immune checkpoint inhibitors in pro grammed deathligand 1 (PDL1)positive advanced nonsmall cell lung cancer [26] . The development of multiplexable and quantitatively more precise proteo mic methods promises new opportunities for biomarker discovery/analysis in the near future. These include using slicebased imaging mass spectrometry [e.g., ma trixassisted laser desorption ionization imaging mass spectrometry (MALDIIMS)] [27] or quantitative multiplex protein analysis using extractbased mass spectrometry (LCMS) [28] .
Genomics
The earliest clinically relevant genomic studies on pre dictive biomarker analysis used in routine diagnostics were the application of fluorescence in situ hybridi zations (FISH) to determine the gene copy number of ERBB2, the HER2 gene, in breast cancer, which could assign it to a positive or negative category for HER2 expression [2, 29, 30] . One of the first examples of large solid tumor profiling is mutation screening for KRAS and NRAS genes in metastatic colorectal carcinoma as a predic tive biomarker for using the EGFR inhibitor panitumu mab [4, 31] . Today, numerous individual examinations of gene mutations or chromosomal aberrations (e.g., trans locations or amplifications) are firmly anchored in the routine diagnostic of different tumors. Currently, new technologies such as massive parallel sequencing (MPS) have been priced into areas where routine diagnostic application has become possible. Those methods have already been adapted to highthroughput screening in routine applications [32] . Implementation of those high throughput approaches has led to improvement of dia gnosis and therapy of different cancer types [33, 34] .
Epigenomics
The first introduced epigenetic biomarker into the rou tine diagnostic was investigation of promoter methyla tion of the MGMT gene using sequencebased techniques to predict response to treatment with temozolomide in glioblastoma [35] . However, newer epigenetic screening approaches, which are still in the process of diagnostic development, focus on the simultaneous investigation of DNA methylation in a large number of coding genes using arraybased or highthroughput sequencing me thods (e.g., Methylseq). Since it is postulated that pathologic methylation patterns in individual tumor enti ties are more stable and reproducible than transcriptome profiles, these technologies are currently being tested primarily in molecular entity assignment. Large studies have substantiated their overall suitability for cancer with unknown primary and for some rare tumor families but have not yet been implemented in the routine diagnostic pipelines [3638] .
Transcriptomics
The analysis of RNA expression signature within can cer cells and CSCs using quantitative polymerase chain reaction (qPCR), arraybased capture, NanoString te chnology or massive parallel RNA sequencing (RNA Seq) approaches has a long tradition in cancer mole cular biomarker analysis. However, individual methods (e.g., quantitative polymerase chain reaction) could never prevail over immunohistology despite partially superior precision. Initially, the parallel analysis of RNA expression patterns was assessed with the hope that diagnostic assignments could be made in unclear cases (e.g., cancer with unknown primary) [39] . Despite their potential and some positive results, these applications could not establish themselves in the wide range of diagnostic services. In addition, many tumor entities 163 WJSC|www.wjgnet.com have been used to develop predictors for the efficacy of conventional chemotherapies based on transcriptomic profiles. Some success in this context has been gene expression tests in breast cancer, which can be used as an additional decisionmaking aid in the therapy stratification of breast cancer patients for adjuvant che motherapy [40] . However, these tests are currently not being used consistently in clinical care.
As indicated, tumors are a pool of heterogeneous cells including CSCs. Inter or intratumor heterog eneity may completely render CSC biomarkers inapt. Seemingly homogenous cell populations that are en riched and purified by a set of wellknown surface markers often hide exceptional heterogeneity. This is more pronounced in the hematological malignancies [16] . Such tumor heterogeneity can be the result of different genetically distinct clones within the tumor due to having various genetic lesions or dysregulation of markers via pathologic epigenetic regulations [2, 4, 4146] .
SINGLE-CELL BASED APPROACHES
Different OMICs approaches have allowed for the discovery and characterization of a variety of cancer related cell populations. However, those approaches are unsuited to capture the heterogeneous nature of cancer cell populations. Therefore, interest was shifted towards characterization of singlecells rather than cell populations. The technical advances that include single cell imaging, genomics or transcriptomics assessed full characterization of different cell populations. The OMICs analysis is usually performed using samples of many cells. However, this type of analysis lacks the kind of de tailed assessment needed for evaluating contribution of individual cells to the overall phenotype. In contrast, singlecell analysis allows comparing the captured OMICs data of thousands of individual cells (Figure 1 ). Applied methods for singlecell isolation have rapidly enhanced in the past few years from manual micromanipulation, cellsearch antibodybased isolation or flowsorting of cells to highthroughput isolation methods using die lectrophoresis (DEP) arrays, microfluidics, emulsion based platforms or 10X genomics Chromium TM single cell controller system. This technical advance could provide massive advantages by significantly increasing the throughput sensitivity and accuracy of employed approaches ( Figure 1B) . One of the prime reasons for using singlecell analysis is to evaluate heterogeneity in seemingly homogenous cell populations. Another reason is to detect small subpopulations that would otherwise be missed in bulk populations. In addition, by using single cell analysis, it is possible to find CSCs and trace them in the circulation, investigate the clonal evolution and mutational rate of cancer cells, to study better the invasion and trace the metastatic dissemination and to understand the molecular mechanisms of therapy resistance of cancer cells and CSCs (Figure 2) .
The first singlecell RNASeq study was published in 2009 [47] . Since then the interest for the approach is growing [48, 49] . Singlecell RNA sequencing is being used for identifying cellular intermediates during deve lopmental processes. Different microfluidic systems have been proposed to isolate single cells and help in library preparation [50] . Several novel methods are available for singlecell analyses. Multiplexed error robust fluo rescence (MERFISH), is a highthroughput method that uses sequential imaging with combinatorial labeling and multiplex single molecule FISH, allowing for robust detection of many genes at the same time in both tissues and cell culture conditions [51] . Another approach is quantitative hybridization chain reaction (qHCR), which uses probes harboring initiators for DNA interac ting with fluorophorelabelled hairpins assembled into polymerase. Using this method, the mRNA expression of thousands of different genes can be captured simul taneously at a singlecell based resolution [52] . Single cell linage tracking allows researchers to follow and trace the fate of individual cells over the time. This also includes the tracing of different cancer cells from primitive CSCs. Lineage tracing by nucleaseactivated editing of ubiquitous sequences (LINNAEUS), is a novel method for cell type identification, characterization and massively parallel linage tracking. In this approach, a double strand break will be introduced to the cells using a CRISPR/Cas9 system, which upon repair, reacts as a unique heritable scar in the daughter cells in order to trace the cellular linages [53] . Pooled screenings rely on readouts that average properties of the cell population of interest. Although these approaches provide an assessment of gene fun ction at the genome scale, they cannot identify the contribution of subpopulations to the bulk phenotype. Moreover, the consequences of distinct perturbations to the overall phenotype cannot be evaluated. To circumvent the problem, methods have been recently developed to study the impact of perturbations at the singlecell levels [54, 55] . These approaches integrate para llel massive singlecell RNASeq and pooled screens to reconstruct the gene regulatory networks controlling particular biological processes. PerturbSeq is a platform for multiplexed profiling of perturbations at the single cell resolution [54] . Profiling the genomic perturbation and the transcriptome in the same cell provides a powerful means to simultaneously the function of multiple factors and their interactions.
Heterogeneity in the tumor cell population was re cently evaluated in different forms of human cancers. In the ovarian cancer, singlecell analysis revealed two major subsets of cells characterized by stromal gene expression patterns [genes associated with epithelial tomesenchymal transition (EMT) and also extracellular 164 WJSC|www.wjgnet.com matrix (ECM) genes] and epithelial gene expression signature (characterized by proliferation and oxidative phosphorylationrelated genes) [56] . Analysis of CSCs in CML, uncovered distinct molecular signatures of leuke mia stem cells with a high level of heterogeneity in the seemingly homogenous cell populations of CSCs [57] . Sin glecell whole exome sequencing (scWES), is a promising tool for detecting subclones and possibly leukemia stem cells in AML [58] . Furthermore, epigenetically distin ct hematopoietic stem cell subpopulations have been detected by highresolution singlecell DNA methyla tion analysis [59] . Singlecell sequencing of glioblastoma and glioma cells also detected a heterogeneous gene expression signature within the tumor population [60, 61] . In breast cancer, regulatory networks influencing stem ness, pluripotency, proliferation, differentiation and EMT have been identified using singlecell gene expression profiling. The analysis has shown that ALDH [62] . Important findings using singlecell sequencing studies on variety of human primary tumors, including bladder, blood, brain, breast, colorectal, kidney, lung and ovarian cancer, are summarized in Table 1 .
SINGLE-CELL T CELL RECEPTOR SEQUENCING OF TUMOR-INFILTRATING LYMPHOCYTES
Most immune cell types can be present in a tumor, and the fraction of immune cells can vary greatly across different tumors and patients [63] . [64] . [65] . Overall, it is clear that complex relationships govern the interactions between immune cells and cancer cells or CSCs.
During T cell development in the thymus, they gain the ability to recognize many different foreign antigens. This ability is assessed by the expression of highly poly morphic surface T cell receptors (TCRs). The enormous diversity of TCRs is resulted by random combinations of genes' segments encoding TCR chains [including variable (V), diversity (D), and joining (J) segments] [66] . Molecu lar profiling and characterization of TCRs in TILs could describe T cell dynamics in different tumors [67] . TILs are typically studied by immunohistochemis try or by flow cytometry, relying on a panel of antibo dies targeting specific markers of immune cells. To 
Bladder cancer
Squamous cell carcinoma RNA-seq Cellular heterogeneity in the gene expression affects the disease outcome [73] Muscle-invasive cell carcinoma SNV-seq Lineage-specific mutations are driving cancer initiation and progress [74] Blood cancer B-cell ALL CNV-seq CNVs were developed as an impact of environmental stressors, which was only detectable at single-cell level [75] Pediatric ALL SNV-seq Analysis revealed clonal somatic mutational prevalence at single-cell resolution [76] Therapy resistant AML RNA-seq Identified molecular signature of resistant LSCs versus therapy-naive LSCs [77] Secondary AML SNV-seq Genomic complexity was identified at single cells which was not seen at bulk leukemic populations [78] CML RNA-seq Single-cell analysis uncovered molecular signature of LSCs [57] JAK2 negative MPN SNV-seq Large genetic distances was observed between mono-clonal tumor cells [79] JAK2V617F MPN RNA-seq Single-cell sequencing revealed the molecular networks driving self-renewal of CSCs [80] Brain cancer EGFR amplified GBM CNV-seq Heterogeneity in EGFR mutations among different tumor cells leading to variation in therapy response [81] GBM RNA-seq Heterogeneity in gene expression panthers was identified including EGFR gene [82] Breast cancer ER + CNV-seq Showed clonal evolution of tumor cells at single-cell resolution [83] HER2 + RNA-seq 404 differentially expressed gene signature was identified in CSCs, which had a prognostic value [84] MDA-MB-231 and CN34 cell lines
RNA-seq
Gene expression profiling identifies small sub-population with more metastatic potential, which was therapy resistant.
[85]
TNBC CNV-seq Showed clonal evolution of tumor cells at single-cell level. Also, chemoresistance evolution in TNBC was identified CNV pattern, while they had regional differences [90] Rectal tumor CNV-seq Multi-region single-cell analysis showed somatic copy number alterations are an early event in cancer development [91] Kidney cancer ccRCC primary carcinoma and paired metastasis RNA-seq Heterogeneity in the expression of targetable genes was identified. The finding highlights the necessity of multi-agent therapies [92] Lung cancer NSCLC RNA-seq Characterization of tumor-infiltrating T cells revealed that inter-tissue effector T cells with a highly migratory nature [93] Clear cell renal cell carcinoma SNV-seq A complex mutational pattern was observed at single-cells compared to bulk tumors [94] Adenocarcinoma PDX RNA-seq Single-cell sequencing identified KRAS + drug resistant cell population within the tumor [95] LC2/ad and LC2/ad-R cell lines RNA-seq Gene expression profiling identifies signature that is linked to therapy resistance [96] Ovarian cancer HGSOC RNA-seq Single-cell analysis could distinguish two major sub-populations within the tumor based on their gene expression signature November 26, 2018|Volume 10|Issue 11| 167 WJSC|www.wjgnet.com complement this approach, gene expression of whole tumors can be used and expression of the immune cell type markers can inform us about the presence of the corresponding cell types [68] . One promising aspect of this approach is that it provides information about the whole transcriptome and is not restricted by the availability of antibodies; however, it is not capable of overcoming the extensive heterogeneity among TILs.
The next generation sequencing approach using genomic DNA (gDNA) as starting material was first used to characterize the TCR diversity in healthy indivi duals [69] and rapidly adapted to TCR profiling in tumor immunology [70] . However, the use of gDNA was more challenging due to the fact that nonproductive TCR re arrangements were also sequenced. In addition, the presence of introns can introduce more technical biases. Therefore, RNAseq was selected as a better approach. Upon introducing more advanced singlecell analysis approaches like microfluidics or 10 × genomics, there was promise to couple RNAseq and TCR sequencing from the same cell, which has the great advantage to identify and characterize very rare T cell populations. A recent work using different singlecell analysis methods investigated the T cell repertoire according to their TCR variability in both mice and human Treg cells [71] . The results of this comprehensive TCR singlecell sequencing revealed that Tregs with some highly activated sub populations could display a broad heterogeneity, while Treg sharing the same antigen recognition specificity were more transcriptionally similar than those with di fferent TCR sequence.
The coupled profiling of TCRs sequencing and single cell gene expression analysis from the same cell pro vides an unbiased classification of T cells based of their TCR signature, which is association of the transcriptional landscape of individual cell [72] . This approach will provide a powerful tool to study the potential impact of TILs on CSCs and will yield valuable insights to personalized im munotherapy of cancer patients.
CONCLUSION
The determination of diagnostic, prognostic and pre dictive biomarkers forms the basis of individualized patient treatment in oncology. As a biomarker, it is demanded to be reproducible, robust and qualityass ured. As of today, the collection of specific biomarkers are not be able to define the complete subsequent of oncological therapy for cancer patients. This affects the efficacy of a treatment, the side effects that a patient is exposed to and the cost of therapy.
Despite some developments in the field of blood based tests and molecular imaging, biomarker analysis in oncology continues to rely essentially on molecular tissue analysis. An exact molecular characterization of CSCs in the tumor requires the development of spe cific markers and suitable enrichment methods. New genomics, epigenomics, transcriptomics and proteomics methods as well as the introduction of novel singlecell based approached will result in an accelerating iden tification of specific oncological biomarkers.
Singlecell technologies are allowing for the detection of molecular changes in individual cancer cells. This can improve investigation of more specific biomarkers with unprecedented resolution leading to build a complete landscape of different cell types within tumors. Single cell analysis of CSCs is challenging mainly due to their rarity and the small amount of total RNA in a single cell. Using a combination of different cellular enrichment strategies, such as flow cytometry for rare cell population like CSCs with the singlecell analyzing methods, will improve the resolution in profiling and characterization of CSCs. Likewise, the ability to amplify and sequence other RNA molecules, such as micro RNAs and long noncoding RNAs, will provide valuable information on gene regulation. New methods to simultaneously pro file genomic DNA variants, DNA methylation and gene expression from the same cell coupled with potential proteomic analysis, could provide powerful tools for assessing the effects of genomic variation and gene expression profiles or epigenetic modifications on can cer cell heterogeneity. Particularly, from highthroughput singlecell based technologies, we can expect valuable insights regarding suitable associated biomarkers to identify and target CSCs. Furthermore, cancer immuno therapy may also benefit from singlecell methods that define the role of TILs within the CSCs and monitor the individual response to the immuneregulatory agents. This would be an important step towards individualized cancer management. 
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